GlassScriptPhysician profile
Sally Mcfarland
NPI 1033220454
$7,566.53
in general payments reported to CMS, 2019-2025
29 companies · $895 in 2025
The $895 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $1,249 · 2021: $1,019 · 2022: $1,027 · 2023: $1,269 · 2024: $872 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,035.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,204.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,130.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $713.37 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $547.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.75 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $500.11 | 2020-2025 | |
| Amneal Pharmaceuticals LLC | $338.50 | 2019-2023 | Unithroid |
| Janssen Pharmaceuticals, INC | $310.83 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $200.82 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.28 | 2022-2025 | |
| Ibsa Pharma INC. | $108.57 | 2021-2022 | |
| Exact Sciences Corporation | $100.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $99.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $80.14 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $74.76 | 2022 | |
| Antares Pharma, INC. | $63.93 | 2019-2023 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceuticals, INC. | $52.35 | 2021 | |
| Amarin Pharma, INC. | $47.75 | 2019-2021 | |
| Allergan, INC. | $42.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $26.49 | 2024 | |
| Astellas Pharma US INC | $22.43 | 2023 | Veozah |
| Teva Pharmaceuticals USA, INC. | $21.69 | 2019 | |
| Linus Health, INC. | $19.25 | 2023 | |
| Corium, LLC | $18.94 | 2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $18.23 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $15.77 | 2025 | Evkeeza |
| Glaxosmithkline, LLC. | $15.23 | 2024 | Arexvy |
| Amgen INC. | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Mcfarland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.